Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check please visit www.ktmc.com.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Cardiovascular Systems, Inc. (NASDAQ: CSII) ("CSI" or the "Company") shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company's securities between September 12, 2011 and January 21, 2016, inclusive (the "Class Period"). Shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (Darren J. Check, Esq. or D. Seamus Kaskela, Esq.) at (888) 299-7706 or at firstname.lastname@example.org. For additional information about this lawsuit, or to request information about this action online, please visit https://www.ktmc.com/new-cases/cardiovascular-systems-inc. CSI is a medical technology company that develops, manufactures, and markets devices to treat vascular diseases, such as Peripheral Arterial Disease ("PAD"). The shareholder class action complaint alleges that CSI and certain of its executive officers made a series of false and misleading statements to investors and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the defendants are alleged to have made materially false and misleading statements to investors and/or failed to disclose that: (1) CSI distributed illegal kickbacks to health care providers; (2) CSI engaged in the off-label promotion of its medical devices; and (3) CSI violated the Food and Drug Administration's laws and regulations in connection with its medical devices. Reminder: CSI shareholders who purchased their securities during the Class Period may, no later than April 12, 2016, petition the Court to be appointed as a lead plaintiff representative of the class. Members of the purported class may petition the Court to be appointed as a lead plaintiff through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.